We are delighted to announce that two new blood cancer drugs have been approved for use in Scotland.
The drugs - idelalisib (Zydelig) for follicular lymphoma, and ofatumumab (Azerra) for chronic lymphocytic leukaemia - have been licensed by the Scottish Medicines Consortium, the organisation that decides which medicines should be provided on the NHS.
As part of the consultation process, Leukaemia & Lymphoma Research gave strong evidence calling for idelalisib to be made available to patients who have not responded to previous treatment. We are thrilled that the SMC listened to us, other charities, clinical experts, and blood cancer patients.
It is only with the dedication and support of our patients and clinicians that we can deliver informed submissions to the bodies that make decisions on drug licensing, and we are deeply appreciative of all the contributions we received.
Since the new appraisal system was introduced last year, the SMC has approved all three of the drugs we have called for. We are proud of this record, and, going forwards, will continue to work closely with our supporters, patients, and clinicians to improve further the lives of all those affected by blood cancer.